E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Asthma in patients who are inadequately controlled by inhaled corticosteroids |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10003553 |
E.1.2 | Term | Asthma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objectives for this study are as follows:
- To assess the efficacy of lebrikizumab in improving asthma control in patients with asthma who remain inadequately controlled despite therapy with Inhaled corticosteroids (ICS).
- To evaluate the safety of lebrikizumab in patients with asthma who remain inadequately controlled despite therapy with ICS. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are as follows:
- To assess the efficacy of lebrikizumab in improving asthma control in patients with asthma who remain inadequately controlled despite therapy with ICS.
- To assess the efficacy of lebrikizumab in reducing the rate of exacerbations in patients with asthma who remain inadequately controlled despite therapy with ICS
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
DNA Repository Substudy in association with Lebrikizumab Study ILR4646g, 19Jun2009. The primary objective of this study is to perform exploratory analyses to generate hypotheses identifying genes associated with treatment response, toxicity, or disease risk. If such genetic hypotheses are identified, they may be tested in future clinical studies within this therapeutic area. |
|
E.3 | Principal inclusion criteria |
Patients must meet the following criteria to be eligible for study entry:
103 Age≥18 to ≤ 65 years at Visit 1.
105 Chest radiography within 12 months of visit 1 with evidence of clinically significant abnormality.
107 Uncontrolled asthma defined by all of the following criteria: - Diagnosis of asthma >12 months. - Bronchodilator response at Visit 1 or 2 - Pre-bronchodilator FEV1 ≥ 40% and ≤ 80% predicted at Visit 3 - Required daily use of ICS ≥ 200 µg and ≤ 1000 µg total daily dose of fluticasone propionate or equivalent for a minimum of 6 months prior to Visit 1 - Demonstrated on-going asthma symptoms assessed at the end of the run-in period by ACQ score ≥ 1.5 (for symptoms over the week prior to visit 3) despite ICS compliance.
|
|
E.4 | Principal exclusion criteria |
Patients who meet any of the following criteria will be excluded from study entry:
a. Medical Conditions 201 Asthma exacerbation, significant airflow obstruction, or respiratory infection between visits 1 and 3.
202 Known malignancy or current evaluation for a potential malignancy. If treatment for a malignancy was completed at least 12 months prior to Visit 1 and no further treatment is anticipated by the patient’s oncologist during this study, then the patient may enroll.
203 Basal or squamous cell carcinoma diagnosed or inadequately treated less than 12 months before Visit 1.
204 Known immunodeficiency, including but not limited to HIV infection.
205 Pre-existing lung disease other than asthma, including active infections.
206 Clinically significant medical disease which is uncontrolled despite treatment or is likely in the opinion of the investigator to require a change in therapy during the study. 207 Patients with elevated IgE levels for reasons other than allergy (including but not limited to parasitic infections, hyperimmunoglobulin E syndrome, and Wiskott-Aldrich, Syndrome).
b. Exposures 210 Current smoker or former smoker with a lifetime smoking history of > 10 pack years.
211 History of substance abuse that may impair or risk the patient’s full participation in the study in the judgment of the investigator.
212 Participation in another interventional clinical trial (including a trial of an approved drug or an interventional study that does not include medication) within 30days or 5 halv-lives if the investigational agent, whichever is longer.
c.Medications 213 Prior allergic reaction during the use (or possible use if blinded study) of a monoclonal antibody.
214 See excluded concomitant and previously prescribed therapies in Table 1 of the protocol.
d.Reproductive Potential 215 Patients (males and females) of reproductive potential who are not willing to use a highly effective method of contraception for the duration of the study or are pregnant or lactating at the time of randomization.
216 Women with a positive serum pregnancy test.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy outcome measure is the relative change in pre-bronchodilator FEV1 (volume) from baseline to Week 12. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 30 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 0 |